In particular, we have shown that a certain percentage of patients with uterine carcinosarcoma and poor prognosis express human epidermal growth factor receptor 2 (HER2), and that trastuzumab deruximab (T-DXd) is effective in both preclinical and clinical settings [9,10]. This evidence concerns the gene ERBB2 and uterine carcinosarcoma.